Image-guided percutaneous microwave ablation for unresectable pancreatic cancers: A multicenter retrospective study

IF 3.2 3区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

European Journal of Radiology Pub Date : 2024-09-21 DOI:10.1016/j.ejrad.2024.111720

Jie Zhou , Gang Dong , Xiang Jing , Guanghui Huang , Zhen Wang , Mengfan Peng , Yan Zhou , Xiaoling Yu , Jie Yu , Zhiyu Han , Fangyi Liu , Hongjian Gao , Yubo Zhang , Zhigang Cheng , Xin Ye , Ping Liang

{"title":"Image-guided percutaneous microwave ablation for unresectable pancreatic cancers: A multicenter retrospective study","authors":"Jie Zhou , Gang Dong , Xiang Jing , Guanghui Huang , Zhen Wang , Mengfan Peng , Yan Zhou , Xiaoling Yu , Jie Yu , Zhiyu Han , Fangyi Liu , Hongjian Gao , Yubo Zhang , Zhigang Cheng , Xin Ye , Ping Liang","doi":"10.1016/j.ejrad.2024.111720","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>This study aims to assess the feasibility, effectiveness, and safety of image-guided percutaneous microwave ablation (PMWA) for unresectable pancreatic cancer.</div></div><div><h3>Methods</h3><div>In this retrospective study, 72 patients from four hospitals were enrolled between November 2009 and October 2022. Descriptive statistics were employed to describe the patients’ characteristics and prognostic factors. The primary endpoint compassed the complete ablation rate (CAR), incidence of complications and the pain relief rate (PRR).</div></div><div><h3>Results</h3><div>The median age of the 72 patients was 61 (interquartile range (IQR) 52.5–67.0) years, with 62.5 % (45/72) being male. 26 cases received computed tomography (CT) guidance; 46 cases received ultrasound guidance. A total of 74 tumors were identified (2 in 2 patients), with 56.8 % (42/74) at the body and tail, and the rest at the head and neck. Overall, 73 ablation sessions were carried out, achieving a technical success rate (TSR) of 100 %. The CAR was 40.5 % (30/74). The median follow-up time was 4.6 (1–43.4) months. 50 % (36/72) of patients had died with a median overall survival (OS) of 5.6 (1–27) months. Regarding complications, 18.1 % (13/72) of cases were classified as grade I and II, and 9.8 % (7/72) as grade IIIa. Before surgery, 33 patients experienced pain symptoms, and the postoperative PRR was 96.7 % (32/33). The average pain score decreased from 6.3 (4–10) before surgery to 2.0 (0–8) after ablation (P<0.001).</div></div><div><h3>Conclusions</h3><div>Image-guided PMWA for unresectable pancreatic cancer is safe and feasible, effectively relieving cancer pain and improving patients’ the quality of life.</div></div>","PeriodicalId":12063,"journal":{"name":"European Journal of Radiology","volume":"181 ","pages":"Article 111720"},"PeriodicalIF":3.2000,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Radiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0720048X24004364","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

This study aims to assess the feasibility, effectiveness, and safety of image-guided percutaneous microwave ablation (PMWA) for unresectable pancreatic cancer.

Methods

In this retrospective study, 72 patients from four hospitals were enrolled between November 2009 and October 2022. Descriptive statistics were employed to describe the patients’ characteristics and prognostic factors. The primary endpoint compassed the complete ablation rate (CAR), incidence of complications and the pain relief rate (PRR).

Results

The median age of the 72 patients was 61 (interquartile range (IQR) 52.5–67.0) years, with 62.5 % (45/72) being male. 26 cases received computed tomography (CT) guidance; 46 cases received ultrasound guidance. A total of 74 tumors were identified (2 in 2 patients), with 56.8 % (42/74) at the body and tail, and the rest at the head and neck. Overall, 73 ablation sessions were carried out, achieving a technical success rate (TSR) of 100 %. The CAR was 40.5 % (30/74). The median follow-up time was 4.6 (1–43.4) months. 50 % (36/72) of patients had died with a median overall survival (OS) of 5.6 (1–27) months. Regarding complications, 18.1 % (13/72) of cases were classified as grade I and II, and 9.8 % (7/72) as grade IIIa. Before surgery, 33 patients experienced pain symptoms, and the postoperative PRR was 96.7 % (32/33). The average pain score decreased from 6.3 (4–10) before surgery to 2.0 (0–8) after ablation (P<0.001).

Conclusions

Image-guided PMWA for unresectable pancreatic cancer is safe and feasible, effectively relieving cancer pain and improving patients’ the quality of life.

查看原文本刊更多论文

图像引导下经皮微波消融治疗无法切除的胰腺癌：多中心回顾性研究

本研究旨在评估图像引导下经皮微波消融术（PMWA）治疗无法切除的胰腺癌的可行性、有效性和安全性。研究采用描述性统计来描述患者的特征和预后因素。主要终点包括完全消融率（CAR）、并发症发生率和疼痛缓解率（PRR）。结果72名患者的中位年龄为61岁（四分位间距（IQR）为52.5-67.0），男性占62.5%（45/72）。26例接受了计算机断层扫描（CT）引导，46例接受了超声引导。共确定了 74 个肿瘤（2 名患者中有 2 个），其中 56.8%（42/74）位于身体和尾部，其余位于头颈部。总共进行了 73 次消融治疗，技术成功率（TSR）为 100%。CAR 为 40.5%（30/74）。中位随访时间为 4.6 (1-43.4) 个月。50%的患者（36/72）已经死亡，中位总生存期（OS）为5.6（1-27）个月。在并发症方面，18.1%（13/72）的病例被列为 I 级和 II 级，9.8%（7/72）被列为 IIIa 级。手术前，33 名患者有疼痛症状，术后 PRR 为 96.7%（32/33）。平均疼痛评分从术前的 6.3 分（4-10 分）下降到消融术后的 2.0 分（0-8 分）（P<0.001）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Radiology 医学-核医学

CiteScore

6.70

自引率

3.00%

发文量

398

审稿时长

42 days

期刊介绍： European Journal of Radiology is an international journal which aims to communicate to its readers, state-of-the-art information on imaging developments in the form of high quality original research articles and timely reviews on current developments in the field. Its audience includes clinicians at all levels of training including radiology trainees, newly qualified imaging specialists and the experienced radiologist. Its aim is to inform efficient, appropriate and evidence-based imaging practice to the benefit of patients worldwide.